drugset / Trial / NCT02633514

Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma

NCT02633514

Phase 3 Withdrawn Fudan University
RandomizedParallel-groupSingle-blindTreatment

Summary

This study is designed to investigate whether adjuvant radiochemotherapy after incomplete resection has a better survival than adjuvant radiotherapy for thymoma or thymic carcinoma.

Timeline

Start
2023-12-01
Primary completion
2024-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 25 mg/m2 Intravenous
Subject Etoposide Small molecule 75 mg/m2 Intravenous

Indications